Product Description
Zileuton is a 5-lipoxygenase inhibitor mainly used for the prophylaxis and treatment of chronic asthma for patients aged 12 and older. Zileuton is used along with inhaled corticosteroids for treatment. It can also be used in patients with aspirin-induced asthma. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/28846301/)
Mechanisms of Action: 5-LOX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Bangladesh | Egypt | India | Pakistan | United Kingdom | United States
Approved Indications: Asthma
Known Adverse Events: Pain Unspecified | Sinusitis
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|